Trevena

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.